TY - JOUR
T1 - Molecular diagnostics in breast cancer routine practice
AU - ter Hoeve, Natalie D.
AU - Moelans, Cathy B.
AU - Schrijver, Willemijne A.M.E.
AU - de Leng, Wendy
AU - van Diest, Paul J.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2017
Y1 - 2017
N2 - The portfolio of adjuvant systemic treatment of breast cancer nowadays contains novel anti-hormonal and chemotherapeutic drugs, immunotherapeutic approaches and small molecules that are only effective in a limited number of patients and are often associated with high costs and significant side effects. Therefore, a personalised approach based on individual tumour biomarkers is required to arrive at the optimal balance between effectiveness on the one hand, and costs and side effects on the other. The aim of this paper is to provide an overview of the molecular biomarkers and associated molecular tests that are currently relevant in pathology of invasive breast cancer.
AB - The portfolio of adjuvant systemic treatment of breast cancer nowadays contains novel anti-hormonal and chemotherapeutic drugs, immunotherapeutic approaches and small molecules that are only effective in a limited number of patients and are often associated with high costs and significant side effects. Therefore, a personalised approach based on individual tumour biomarkers is required to arrive at the optimal balance between effectiveness on the one hand, and costs and side effects on the other. The aim of this paper is to provide an overview of the molecular biomarkers and associated molecular tests that are currently relevant in pathology of invasive breast cancer.
KW - Breast cancer
KW - Molecular biomarkers
KW - Pathology
UR - http://www.scopus.com/inward/record.url?scp=85020796642&partnerID=8YFLogxK
U2 - 10.17925/EOH.2017.13.01.74
DO - 10.17925/EOH.2017.13.01.74
M3 - Review article
AN - SCOPUS:85020796642
SN - 2045-5275
VL - 13
SP - 74
EP - 79
JO - European Oncology and Haematology
JF - European Oncology and Haematology
IS - 1
ER -